1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Cohance Lifesciences Ltd

Cohance Lifesciences Ltd

448.65
INR
-7.25
(-1.59%)
1.52EPS
163.04P/E
173.17BMarket Cap
Nov 02Next Earn
Cohance Lifesciences Ltd
BSE:COHANCE
(Bombay Stock Exchange)

Recent

price

448.65

P/E

ratio

163.04

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
14.52
32.1
39.1
51.34
52.29
40.62
66.28
57.62
55.97
Revenue per Share
4.29
12.45
14.23
17.83
16.16
11.8
12.79
4.69
2.78
Basic EPS, GAAP
-0.25
11.94
10.67
10.01
6.73
13.08
9.35
3.88
- -
Free Cash Flow per Basic Share
0.9
3.01
1
4
8
- -
- -
- -
- -
Dividend per Share
23.19
33.18
46.38
59.99
68.16
80.56
143.34
102.24
- -
Book Value per Share
23.08
33.07
46.28
59.9
65.72
78.12
90.49
66.08
- -
Tangible Book Value per Share
255
255
255
255
255
255
381
382
383
Basic Weighted Avg Shares
3,696
8,173
9,955
13,070
13,311
10,341
25,262
22,038
21,415
Sales/Revenue/Turnover
44.1
44.22
41.32
41.56
39.54
34.27
26.27
11.22
5.81
Operating Margin (%)
115
237
312
383
465
546
1,668
1,873
1,917
Depreciation Expense
1,093
3,170
3,623
4,538
4,113
3,003
4,873
1,792
1,062
Net Income, GAAP
30.78
21.63
22.52
32.02
26.52
25.98
24.65
27.49
42.28
Effective Tax Rate (%)
29.57
38.79
36.4
34.72
30.9
29.04
19.29
8.13
4.96
Profit Margin (%)
2,321
1,913
3,450
9,176
8,523
11,354
10,881
11,820
- -
Working Capital
- -
918
363
289
53
212
3,209
2,561
- -
LT Debt
5,903
8,448
11,808
15,272
17,352
20,507
37,929
40,338
- -
Total Equity
- -
33.14
27.01
25.01
22.62
13.26
14.65
3.63
- -
Return on Invested Capital (%)
- -
39.04
31.38
31.07
24.53
15.58
16.23
5.36
- -
Return on Capital (%)
- -
44.18
35.78
33.52
25.21
15.86
17.1
4.74
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1,444
- -
LT Borrowings
- -
505
- -
LT Finance Leases
- -
2,056
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
383
383
383
Market Capitalization
202,187
115,497
173,169

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
18,280
- -
Cash, Cash Equivalents & STI
- -
3,201
- -
Accounts Receivable, Net
- -
6,810
- -
Inventories
- -
5,622
- -
Total Current Liabilities
- -
6,459
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,444
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
30.49%
6.35%
Free Cash Flow
- -
0.82%
-58.37%
Net Income, GAAP
- -
-2.41%
-63.22%
Sales/Revenue/Turnover
- -
28.47%
-12.76%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
4,881
6,038
6,762
8,404
25,262
2026
5,493
5,556
5,446
6,191
22,038
2027
4,223
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.96
5.44
6.01
4.73
12.79
2026
1.28
1.94
0.96
0.51
4.69
2027
-0.63
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Cohance Lifesciences Limited (COHANCE.NS), formerly Suven Pharmaceuticals Limited, is an India-based, technology-driven contract development and manufacturing organization (CDMO) that provides end-to-end contract research, development, and manufacturing services for new chemical entity (NCE)-based intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations to global pharmaceutical, biotechnology, and fine chemical companies. The company offers comprehensive CDMO services including custom synthesis, process research and development, scale-up, and contract manufacturing of intermediates, APIs, and formulations; clinical, analytical, and research services; finished dosage formulations; specialty chemicals such as electronic chemicals; and advanced solutions in complex chemistries like cyanation and heterocyclic compounds covering pyrimidines, quinolones, thiazoles, and imidazoles, with core competencies supporting challenging development and manufacturing needs across clinical trial materials, regulatory support, quality assurance, and supply chain management. Founded in 1989 and headquartered in Hyderabad, India, with manufacturing facilities in Genome Valley and R&D centers there, Cohance Lifesciences operates geographically in India, the USA (through subsidiary NJ Bio Inc. in Princeton, New Jersey), Europe, and the rest of the world, serving leading global life science innovators as a subsidiary of Berhyanda Limited. Recent major developments include its name change from Suven Pharmaceuticals Limited in May 2025 following the completion of a merger with Cohance Lifesciences that received final Department of Pharmaceuticals approval in 2025 to create an integrated global CDMO platform focused on high-growth modalities; a USD 10 million investment announced in August 2025 to establish a cGMP bioconjugation suite at NJ Bio for up to 2 kg Antibody-Drug Conjugate (ADC) production for Phase 2b clinical supply, operational by Q4 FY26; Rs 230 million investment in a new cGMP oligonucleotide facility in Hyderabad; and a USD 16.5 million corporate guarantee extended in July 2025 to Citibank N.A. to support NJ Bio's USD 15 million credit facility for bioconjugation operations through June 2028.